Study S000119

A Randomized, Open-label, Clinical Trial Evaluating the Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT07254572
Acronym: CASCADES
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 300
Start: 2025-07-10
Primary completion: 2029-08-01
Lead sponsor: National Institute of Cardiology, Warsaw, Poland
Conditions: Coronary Artery Disease; PreDiabetes
Interventions: DRUG:Semaglutide 14 MG [Rybelsus]; DRUG:Dapagliflozin (Forxiga); DRUG:Metformin; BEHAVIORAL:Optimal Medical Therapy (OMT) And Lifestyle Intervention
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Evaluation of the effect of GLP-1 analogue treatment on coronary artery disease progression AND Evaluation of the effect of flozin treatment on the progression of coronary artery disease (CO-PRIMARY ENDPOINTS) [24 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.